Daclatasvir

CAS No.	1009119-64-5	Cat. No.	BCP02431
Name	Daclatasvir
Synonyms	BMS790052; EBP-883; EBP 883; EBP883;BMS 790052;BMS790052; Daklinza;
Formula	C40H50N8O6	M. Wt	738.89

Description	Daclatasvir is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antiviral agents to treat chronic hepatitis C. Elevations in serum enzyme levels during daclatasvir therapy are uncommon, and it has yet to be convincingly implicated in cases of clinically apparent liver injury with jaundice. Nevertheless, and for unknown reasons, successful all-oral regimens of antiviral therapy in patients with chronic hepatitis C and cirrhosis is occasionally complicated by hepatic decompensation and may cause reactivation of hepatitis B in susceptible patients coinfected with the hepatitis B virus (HBV).
Pathways	Protease/Metabolic Enzyme Microbiology/Virology
Targets	HCV Protease HCV

Different Interaction Profiles of Direct-Acting Anti-Hepatitis C Virus Agents with Human Organic Anion Transporting Polypeptides Publications Citing of Biochempartner's Daclatasvir(CAS:1009119-64-5)

Publications Citing of Biochempartner's Daclatasvir(CAS:1009119-64-5)

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.